6月2日 演題レポート
Abstract #3538
Cetuximab and Chemotherapy in the Treatment of Patients with Initially "Non-resectable" Colorectal (CRC) Liver Metastases: Long Term Follow-up of the CELIM trial.
Gunnar Folprecht, et al.
Abstract #3611
Quality of Life (QOL) and Toxicity among Patients in CALGB 80405.
Michelle J. Naughton, et al.
Abstract #3613
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients.
Marta Schirripa, MD
Abstract #3616
SPIRITT (Study 20060141): A Randomized Phase 2 Study of FOLFIRI with Either Panitumumab or Bevacizumab as 2nd-line Treatment in Patients with Wild-Type (WT) KRAS Metastatic Colorectal Cancer (mCRC).
Allen L. Cohn, et al.
Abstract #3617
Comprehensive Analysis of KRAS and NRAS Mutations as Predictive Biomarkers for Single Agent Panitumumab (Pmab) Response in a Randomized, Phase 3 Metastatic Colorectal Cancer (mCRC) Study (20020408).
Scott D. Patterson, et al.
Abstract #3620
Overall Survival (OS) Analysis from PRIME : Randomized Phase III Study of Panitumumab (pmab) with FOLFOX4 for 1st-line Metastatic Colorectal Cancer (mCRC).
Jean-Yves Douillard, et al.
Abstract #3631
Analysis of KRAS / NRAS Mutations in PEAK: A Randomized Phase 2 Study of FOLFOX6 + Panitumumab or Bevacizumab as 1st-Line Treatment for Wild Type (WT) KRAS (exon 2) Metastatic Colorectal Cancer (mCRC).
Lee S. Schwartzberg, et al.
Abstract #3636 / #3637
Abstract #3636
Regorafenib (REG) in Progressive Metastatic Colorectal Cancer (mCRC): Analysis of Age Subgroups in the Phase III CORRECT Trial.
Eric Van Cutsem, et al.
Abstract #3637
Time Profile of Adverse Events (AEs) from Regorafenib (REG) Treatment for Metastatic Colorectal Cancer (mCRC) in the Phase III CORRECT Study.
Axel Grothey, et al.
